ReviewCancers2019
The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
155 citing papers in PubMed, 4 syntheses or guidelines pooled it, 243 citations in OpenAlex.
- Curcumin in ovarian cancer: mechanistic insights and translational potential.Medical oncology (Northwood, London, England) · 2026Pooled it
- Integrative Meta-Analysis Identifies Epithelial-Mesenchymal Transition Gene Signatures as Key Determinants of Ovarian Cancer Progression and Treatment Outcome.International journal of molecular sciences · 2026Pooled it
- Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.Cancer medicine · 2022Pooled it
- Diabetes mellitus and the risk of ovarian cancer: a systematic review and meta-analysis of cohort and case-control studies.BMJ open · 2020Pooled it
- Systems-Level Mapping of the Tumor Microenvironment Reveals Immune-Mediated Mechanisms and Potential Targets in Platinum-Resistant Ovarian Cancer.Research square · 2026Article
- Oncogenic EGFR Signaling as a Central Regulator of Chemoresistance in Ovarian Cancer: A Mechanistic Review.International journal of molecular sciences · 2026Review
- Pre-operative circulating tumor cells predict worse treatment outcome in patients with high-grade serous ovarian cancer.Oncogene · 2026Article
- Cycloastragenol Inhibits Colorectal Cancer Cell Metastasis via Epithelial-Mesenchymal Transition and the PI3K Signalling Pathway.Journal of cellular and molecular medicine · 2026Article
- Critical roles of Hedgehog signaling pathway in regulating the multidrug resistance of ovarian cancer.Journal of ovarian research · 2026Review
- Metastatic organotropism in peritoneal metastasis: Paget's hypothesis revisited.Clinical and experimental medicine · 2026Review
- Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy.International journal of molecular sciences · 2026Review
- Nanotechnology-Assisted Co-Delivery of Immunotherapeutic Agents for Targeting Ovarian Cancer: Prospects and Challenges.International journal of nanomedicine · 2026Review
- The role of the microbiome in gynecological cancers: implications for diagnosis and treatment.Frontiers in immunology · 2026Review
- A Novel Partial EMT-Associated Transcriptomic Signature for Prognostic Stratification in Ovarian Cancer.Oncology research · 2026Article
- Loss of CD90 alters EMT-associated features and drug sensitivity in U-CH1 chordoma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Distinct origins of high-grade serous ovarian carcinoma: genetic and epigenetic evidence linking ovarian and fallopian tube epithelium to clinical outcomes and early detection.Molecular biology reports · 2025Review
- The Emerging Role of FAM171A2 in Gynecological Malignancies: Bioinformatic Insights from UCEC and Ovarian Cancer.International journal of molecular sciences · 2025Article
- Mesenchymal-epithelial transition reduces proliferation but increases immune evasion in tumor spheroids.iScience · 2025Article
- Signaling networks and MiRNA crosstalk in ovarian cancer chemoresistance.Journal of ovarian research · 2025Review
- Cold atmospheric plasma-activated liquid inhibits peritoneal metastasis in drug-resistant ovarian cancer by targeting the epithelial-mesenchymal transition.Clinical & experimental metastasis · 2025Article
95 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Ovarian cancer is the most lethal of all gynecologic malignancies and the eighth leading cause of cancer-related deaths among women worldwide. The main reasons for this poor prognosis are late diagnosis; when the disease is already in an advanced stage, and the frequent development of resistance to current chemotherapeutic regimens. Growing evidence demonstrates that apart from its role in ovarian cancer progression, epithelial-to-mesenchymal transition (EMT) can promote chemotherapy resistance. In this review, we will highlight the contribution of EMT to the distinct steps of ovarian cancer progression. In addition, we will review the different types of ovarian cancer resistance to therapy with particular attention to EMT-mediated mechanisms such as cell fate transitions, enhancement of cancer cell survival, and upregulation of genes related to drug resistance. Preclinical studies of anti-EMT therapies have yielded promising results. However, before anti-EMT therapies can be effectively implemented in clinical trials, more research is needed to elucidate the mechanisms leading to EMT-induced therapy resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.